logo-loader
Allergy Therapeutics PLC

Allergy Therapeutics expects earnings to come in ahead of market expectations

Allergy Therapeutics PLC's (LON:AGY) CFO Nick Wykeman talks Proactive London's Andrew Scott through their trading update for the year to the end of June 2019.

He says net revenue for the year's expected to be £73.7mln, up 8% on last year, while cash at the end of June was £27.4mln.

That means the group has the funds to fully finance from existing resources the phase III clinical trial of its new short-form grass allergy inoculation due to start next autumn.

Quick facts: Allergy Therapeutics PLC

Price: £0.12

Market: AIM
Market Cap: £73.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Allergy Therapeutics on track for phase III grass pollen trial in 2019

Manuel Llobet, chief executive of Allergy Therapeutics plc (LON:AGY), spoke to Proactive Investors after reporting  “extremely positive results” from the phase II trial of their grass pollen-induced hay fever immunotherapy. Llobet says PQ Grass met its primary endpoint, with those...

on 21/5/18

2 min read